Advisory Board and Editors Drugs & Devices
Audrey R Odom John
Chief, Division of Infectious Diseases, Children's Hospital of Philadelphia
The primary research goals of our lab are to understand the biological functions of specific metabolic pathways in the malaria parasite--that is, to understand what the parasite needs to make, and why it needs to make it.
Sonia MR Oliveira
Doctor Sonia Oliveira holds a Licenciatura in Biology (pre-Bologna) and a Master in Cellular and Molecular Biology from the University of Aveiro, where she also specialized in medicinal plants, toxicology, murine models, and spermatogenesis. In 2011 she moved to Australia to work in Reproductive Biological Sciences. She later explored the nerve-cancer connection in Cancer, namely in female cancers, and completed her Ph.D. in Human Physiology ( with a significant component in Medical Biochemistry and Neurophysiology) from the University of Newcastle (Australia) in 2018. She then worked with biomimetic systems and nanotechnology in diabetes and stem cells. She explored multiple methods for primary and secondary cell culture, always with a keen interest in histopathology, cell biology, and rare disorders. Participated in >40 event(s). (Co-)Supervised MSc dissertation(s) and final projects for course completion of LSc/BSc. And works mostly in the area(s) of Natural sciences with emphasis on Molecular and Cellular Biology, and Medical and Health Sciences with emphasis on Neurosciences, Cancer, Reproduction, Toxicology, Biotechnology, and Stem cells. Also has collaborations in Microbiology, Biomaterials, and Communication and Information technologies.
Adegboyega K Oyelere
Educational Background: B.Sc. Chemistry (Industrial Option), 1st Class Honors, 1992, University of Ibadan, Nigeria. Ph.D. Organic Chemistry, 1998, Brown University, Providence Rhode Island
Employment History:
July 1998 – Nov. 2001: Postdoctoral Associate and Jane Coffin Childs Postdoctoral Fellow, Dept. of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut.
Nov. 2001 – Jan. 2004: Research Scientist II, Rib-X Pharmaceuticals, Inc.
Jan. 2004 – Aug. 2005: Senior Research Scientist, Rib-X Pharmaceuticals, Inc.
Aug. 2005 – April 2011: Assistant Professor, Chemistry and Biochemistry Georgia Institute of Technology, Atlanta.
Dec. 2007 – Nov. 2009: Blanchard Assistant Professor, Chemistry and Biochemistry Georgia Institute of Technology, Atlanta.
April 2011 – March 2022: Associate Professor, Chemistry and Biochemistry Georgia Institute of Technology, Atlanta.
March 2022 – Present: Professor, Chemistry and Biochemistry Georgia Institute of Technology, Atlanta.
Maura Pellei
Maura Pellei is Associate Professor of General and Inorganic Chemistry at the University of Camerino. In 1993 she graduated in biological science at the University of l′Aquila. She obtained her degree in chemistry in 2003 and her Ph.D. in chemical sciences in 2010 at the University of Camerino. Her research interests are in coordination
chemistry, bioinorganic systems, and metal-based drugs.
Jiangjiang Qin
Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).
Dr. Qin received his B.S. degree in Pharmacy (2006) and Ph.D. in Biomedical Engineering with the highest honor (2011) from Shanghai Jiao Tong University, China, under the supervision of Professor Wei-Dong Zhang. After completion of Post-Doctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC) in 2014, Dr. Qin continued his research work at TTUHSC as a Research Associate and a Senior Research Associate and at the University of Houston as a Senior Research Scientist. Dr. Qin joined Zhejiang Chinese Medicinal University as a Full Professor in 2018 and then moved to IBMC in 2020.
Dr. Qin’s research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 150 research papers and reviews. He is also an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an Editorial Board Member of more than 10 scientific journals such as Recent Patents on Anti-Cancer Drug Discovery, Journal of Cancer Research Updates, World Journal of Traditional Chinese Medicine.
Maria Valeria Raimondi
Prof. Dr. Maria Valeria Raimondi, PhD is Assistant Professor in Medicinal Chemistry, University of Palermo, Italy.
In 2018 and 2020, Dr. Raimondi's was a visiting Scientist in Medicinal Chemistry at the University of Vienna and the University of Hamburg respectively. Prior to this Dr. Raimondi was Assistant Professor in Medicinal Chemistry at the University of Palermo
Her scientific interests include:
-Synthesis and antimicrobial evaluation of new compounds with phenoxyacetamidic and iodobenzamidic structure
-Synthesis and antiproliferative activity of new derivatives with triazenic, tetrazepinonic and indazolocarboxyamidic structure
-Design and synthesis of new derivatives with a 4-quinazolinone structure, potential inhibitors of folate receptors
-Synthesis of new pyrrole derivatives related to pyrrolomycin inhibitors of Sortase A
-Synthesis of pyrazole and indazole derivatives, potential inhibitors of CDK1
-Identification of new sigma receptor ligands. Design and synthesis of a beta-aminoketones drug discovery library
-Microwave-assisted organic synthesis (MAOS) of compounds with potential antitumor activity
-Synthesis of polycyclic structures with marked antitumor activity in vitro
-Qualitative and quantitative analysis of industrial hydrocolls from the citrus industries
http://orcid.org/0000-0003-3143-738X
Scopus Author ID: 7006063479
David Rodríguez-Sanz
Dr. David Rodríguez-Sanz is a professor at the Universidad Complutense de Madrid, Spain.
His main research interest is focused in the field of foot and ankle, muscle, tendon, biomechanics, sports.
Camillo Rosano
A physicist; in 1996 Camillo Rosano started his studies in Macromolecular Crystallography at the Advanced Biotechnology Center, Genova (I). In 1997 he achieved the Advanced Certificate in Principles of Protein Structures (PPS), Birkbeck College, University of London, UK, and in 1998 he spent a period at the “York Structural Biology Laboratory” York University, York, UK for a Macromolecular crystallography traineeship. He participated to the NASA expeditions STS100/ISS6A and STS110/ISS7A by designing experiment of protein crystallization on-board the International Space Station (ISS). Director of different Courses and Workshops, he is the author/coauthor of more than 100 peer-reviewed scientific publications.
Dr. Rosano is a Full Professor in Biochemistry and Full Professor in Applied Biology. Italian Ministry for University, Education and Research (MIUR), 2012.
Mirela Sedic
Dr Mirela Sedic (born Bauman) is Principal Scientist at the Institute for Anthropological Research Zagreb. She has authored over 50 scientific publications in peer-reviewed journals including high-impact journals such as BBA Molecular Basis of Disease, Molecular Cancer, The Journal of Pathology, Molecular Cancer Therapeutics, Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry and Cancer Treatment Reviews.
She was the co-PI of international collaborative project with Functional Genomics Center Zurich in Switzerland (PRIME-XS-0000184 Proteomic profiling of retinal proteins from rat model of age-related macular degeneration 2012-2014) and the PI of the University of Rijeka grant “Screening and biological evaluation of acid ceramidase and sphingosine kinase inhibitors as a new class of anti-tumour agents” (2014 – 2017). She is currently the PI of the project funded by the Croatian Science Foundation “Dissecting the mechanisms of therapy resistance in BRAF-mutant colon cancer using an integrated –omics approach” (2019 – 2023) and the PI of the University of Rijeka research grant “Molecular features associated with BRAFV600E-mutated versus wild type BRAF colorectal cancer” (2019-2022). She is also the PI of the project No. 3238 - EPIC-XS 012: “Proteomic analysis of acquired resistance to vemurafenib in BRAF V600E–mutant colon cancer cells” (2019 - 2022) in collaboration with the Functional Genomics Center Zurich in Switzerland.
Arif J Siddiqui
Dr. Arif Jamal Siddiqui is an Associate Professor and Principal Investigator at the Department of Biology, College of Science, University of Hail, Saudi Arabia. He received his PhD from CSIR-Central Drug Research Institute, Lucknow, India in 2015. From 2015 to 2018, he worked as a Post-Doctoral Fellow at Texas Tech University Health Sciences Center, Lubbock, Texas, United States of America.
He has more than 8 years of experience in research, teaching and administration. In his professional work, he has received research grants as a Principal Investigator from various renowned organizations. He has successfully published more than 100 publications in internationally recognized peer-reviewed prestigious journals, published several book chapters for internationally renowned publishers and presented many articles and posters in various conferences/workshops worldwide. He has published numerous papers in the fields of parasitology, immunology, herbal medicine, vaccine development, drug discovery and natural products with a specialization in anti-parasitic, antiviral, anticancer and antibacterial agents. Furthermore, he is a member of The Indian Science Congress Association, India and the Annals of Parasitology, Poland. He has reviewed more than 250 manuscripts and he also currently holds various editorial positions (Academic, Associate, Guest and Review Editor) in various reputable journals and has edited more than 150 manuscripts.
Claudiu T. Supuran
Claudiu T. Supuran is professor of medicinal and pharmaceutical chemistry at the University of Florence, Italy, since 1995. He did his Ph D at University of Bucharest, Romania, and was a visiting scholar at University of Florida, Gainesville, USA, and at Grifitth University, Brisbane, Australia. He was visiting professor at University of La Plata, Argentina and at University of New South Wales, Sydney, Australia. His main research interest is the medicinal chemistry/biochemistry of carbonic anhydrases, field in which he has made contributions to the design of many novel classes of enzyme inhibitors and activators, deciphering their mechanism of action at molecular level, discovery of new isoforms and their role in disease (cancer, obesity, epilepsy, neuropathic pain and cognition), discovery and characterization of carbonic anhydrases from various organisms (bacteria, fungi, corals, vertebrates other than humans and rodents, etc). Other research interests include X-ray crystallography of metallo-enzymes, heterocyclic chemistry, chemistry of sulfonamides, metal-based drugs, cyclooxygenases, serine proteases, matrix metalloproteinases, bacterial proteases, and amino acid derivatives among others. He has published more than 1500 papers in these fields and his Hirsch index is 134. One of the compounds discovered in his laboratory (SLC-0111) is in Phase II clinical trials for the treatment of advanced metastatic solid tumors
Charles H Williams
Dr. Charles (Chuck) Williams is an Assistant Professor at Michigan State University, and is a basic scientist whose research centers on chemical genetics of vertebrate development and early drug discovery. His research functions at the intersection of developmental biology, chemical biology, computational biology, and personalized medicine. Dr. Williams' work includes innovative chemical biologic approaches to study embryonic development as well as developing resources to facilitate academic drug discovery.
His research has made contributions to the emerging field of chemical genetics through the discovery of chemical modulators of several key developmental pathways, including the Eggmanone, a small molecule inhibitor of the Hedgehog pathway. This work revealed novel biological insights and new therapeutic opportunities for targeting cancers downstream of the Smoothened receptor which handles the clinical problem of acquired smoothened resistance in medulloblastoma. In addition, Dr. Williams edited a book covering the latest methods and protocols in chemical biology. He has recently co-founded a start-up around a new technology for targeting glioblastoma.
Dr. Williams received a PhD in cell and developmental biology from Vanderbilt University, where he also received his BS in Molecular and Cellular Biology.